Literature DB >> 12490665

Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese.

Rosane Ness-Abramof1, Dan Nabriski, Caroline M Apovian, Mark Niven, Eliahu Weiss, Menachem S Shapiro, Louis Shenkman.   

Abstract

OBJECTIVE: Reevaluation of the validity of the 1-mg overnight dexamethasone suppression test (ODST) as a screening test for Cushing's syndrome in obese patients. RESEARCH METHODS AND PROCEDURES: Eighty-six obese patients (body mass index, 30 to 53 kg/m(2)) that were referred to a general endocrine outpatient clinic for evaluation of simple obesity, diabetes mellitus, hypertension, polycystic ovary disease, or pituitary tumor. One milligram dexamethasone was administered orally at 11:00 PM, and serum cortisol levels were measured the following morning between 8:00 AM and 9:00 AM. Suppression of serum cortisol to <80 nM (3 micro g/dL) was chosen as the cut-off point for normal suppression. Patients with serum cortisol levels > or =80 nM were evaluated for Cushing's syndrome.
RESULTS: Suppression of morning cortisol levels to <80 nM occurred in 79 of the 86 obese patients. Seven patients had serum cortisol levels higher than 80 nM; five were eventually diagnosed with Cushing's syndrome and two were considered false positive results in view of normal 24-hour free urinary cortisol and normal suppression on a low dose dexamethasone suppression test (0.5 mg of dexamethasone every 6 hours for 2 days). We found a false positive rate of 2.3% for the ODST using a cut-off serum cortisol of 80 nM. DISCUSSION: The ODST is a valid screening test for Cushing's syndrome in the obese population. The false positive rate was 2.3%, even when using a strict cut-off serum cortisol of 80 nM. Abnormal cortisol suppression in obese patients should be investigated and not be considered false positive results.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12490665     DOI: 10.1038/oby.2002.166

Source DB:  PubMed          Journal:  Obes Res        ISSN: 1071-7323


  11 in total

Review 1.  Pros and cons of screening for occult Cushing syndrome.

Authors:  Antoine Tabarin; Paul Perez
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

2.  Carbamazepine and false positive dexamethasone suppression tests for Cushing's syndrome.

Authors:  Ronald C W Ma; Wing Bun Chan; Wing Yee So; Peter C Y Tong; Juliana C N Chan; Chun Chung Chow
Journal:  BMJ       Date:  2005-02-05

3.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; John Newell-Price; Martin O Savage; Paul M Stewart; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-03-11       Impact factor: 5.958

4.  Indications for Surgery for Obesity and Weight-Related Diseases: Position Statements from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO).

Authors:  Maurizio De Luca; Luigi Angrisani; Jacques Himpens; Luca Busetto; Nicola Scopinaro; Rudolf Weiner; Alberto Sartori; Christine Stier; Muffazal Lakdawala; Aparna G Bhasker; Henry Buchwald; John Dixon; Sonja Chiappetta; Hans-Christian Kolberg; Gema Frühbeck; David B Sarwer; Michel Suter; Emanuele Soricelli; Mattias Blüher; Ramon Vilallonga; Arya Sharma; Scott Shikora
Journal:  Obes Surg       Date:  2016-08       Impact factor: 4.129

5.  Prevalence of endocrine diseases in morbidly obese patients scheduled for bariatric surgery: beyond diabetes.

Authors:  Paola Fierabracci; Aldo Pinchera; Silvia Martinelli; Giovanna Scartabelli; Guido Salvetti; Monica Giannetti; Andrea Pucci; Giulia Galli; Ilaria Ricco; Giorgia Querci; Teresa Rago; Claudio Di Salvo; Marco Anselmino; Paolo Vitti; Ferruccio Santini
Journal:  Obes Surg       Date:  2011-01       Impact factor: 4.129

Review 6.  Screening for Cushing's syndrome: is it worthwhile?

Authors:  Ilan Shimon
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

7.  Discovery of Cushing's Syndrome After Bariatric Surgery: Multicenter Series of 16 Patients.

Authors:  Bradley R Javorsky; Ty B Carroll; Nicholas A Tritos; Roberto Salvatori; Anthony P Heaney; Maria Fleseriu; Beverly M K Biller; James W Findling
Journal:  Obes Surg       Date:  2015-12       Impact factor: 4.129

8.  Is it worthwhile to screen patients with type 2 diabetes mellitus for subclinical Cushing's syndrome?

Authors:  Sweta Budyal; Swati Sachin Jadhav; Rajeev Kasaliwal; Hiren Patt; Shruti Khare; Vyankatesh Shivane; Anurag R Lila; Tushar Bandgar; Nalini S Shah
Journal:  Endocr Connect       Date:  2015-09-29       Impact factor: 3.335

Review 9.  Variability in laboratory parameters used for management of Cushing's syndrome.

Authors:  Francesca Pecori Giraldi; Alberto G Ambrogio
Journal:  Endocrine       Date:  2015-07-10       Impact factor: 3.633

10.  Routine Screening for Cushing's Syndrome Is Not Required in Patients Presenting with Obesity.

Authors:  Serap Baydur Sahin; Hacer Sezgin; Teslime Ayaz; Emine Uslu Gur; Kadir Ilkkilic
Journal:  ISRN Endocrinol       Date:  2013-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.